The mice were injected via the tail vein with 2 μg galectin-3, equivalent to 1.25 μg/ml blood (assuming 1.6 ml total blood volume), a pathological circulating galectin-3 concentration found in patients with metastatic cancer, or PBS to control mice, 24 hr prior to the administration of tumor cells to prime the mice. The gene discussed is LGALS3; the disease is metastatic malignant neoplasm.